for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oragenics Inc

OGEN.A

Latest Trade

0.71USD

Change

-0.02(-2.13%)

Volume

332,920

Today's Range

0.68

 - 

0.71

52 Week Range

0.38

 - 

1.80

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.72
Open
0.69
Volume
332,920
3M AVG Volume
133.51
Today's High
0.71
Today's Low
0.68
52 Week High
1.80
52 Week Low
0.38
Shares Out (MIL)
115.64
Market Cap (MIL)
87.55
Forward P/E
-3.79
Dividend (Yield %)
--

Next Event

Oragenics Inc Annual Shareholders Meeting

Latest Developments

More

Oragenics Announce Changes In Management And Board Of Directors

Oragenics Prices $5.25 Million Common Stock Offering

Oragenics Says FDA Supports Co’s Pre-IND Development Program For SARS-CoV-2 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oragenics Inc

Oragenics, Inc. is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. The Company’s pre-clinical product candidates includes OG716 and Terra CoV-2. The Company, through its subsidiary, is engaged in the research and development of Terra CoV-2 vaccine product candidate. It is also engaged in the development of its lead lantibiotic candidate, OG716, to treat Clostridium difficile.

Industry

Business Services

Contact Info

4902 Eisenhower Blvd Ste 125

TAMPA, FL

33634-6342

United States

+1.813.2867900

https://www.oragenics.com/

Executive Leadership

Frederick W. Telling

Executive Chairman of the Board

Michael O Keefe Sullivan

Interim Principal Executive Officer, Chief Financial Officer, Treasurer, Company Secretary

Kim Murphy

Director

Alan William Dunton

Independent Director

Robert C Koski

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.870

2019

-0.370

2020

-0.470

2021(E)

-0.200
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.32
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-105.78
Return on Equity (TTM)
-100.00

Latest News

Latest News

BRIEF-Oragenics Provides Update On COVID-19 Program

* ORAGENICS INC - TERMINATES AG013 ORAL MUCOSITIS DEVELOPMENT PROGRAM

BRIEF-Oragenics Board Approved Amendment To Employment Agreement With CEO

* ORAGENICS INC - BOARD APPROVED SECOND AMENDMENT TO EMPLOYMENT AGREEMENT WITH ALAN JOSLYN, CO’S CEO

BRIEF-Oragenics Files For Shelf Of Up To 18.4 Mln Common Shares By Selling Stockholders

* ORAGENICS INC FILES FOR SHELF OF UP TO 18.4 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS – SEC FILING Source text: (https://bit.ly/3cft9Aj) Further company coverage:

BRIEF-Oragenics Announces New Member Of The Board Of Directors

* ORAGENICS INC - INCREASED SIZE OF BOARD & APPOINTED KIM MURPHY TO BOARD, EFFECTIVE MAY 1, 2020

BRIEF-Oragenics Acquires Noachis Terra Inc

* ORAGENICS ACQUIRES NOACHIS TERRA INC., TO DEVELOP ITS TERRACOV2 NIH-GENERATED SARS-COV-2 (COVID 19) VACCINE CANDIDATE UTILIZING “SPIKE PROTEIN”

BRIEF-Oragenics Says Phase 2 Clinical Trial Of Ag013 Did Not Demonstrate Statistical Significance On Primary Endpoint

* ORAGENICS, INC. ANNOUNCES EARLY TOP-LINE RESULTS OF PHASE 2 CLINICAL TRIAL OF AG013 FOR ORAL MUCOSITIS IN CHEMORADIATION TREATMENT OF HEAD AND NECK CANCER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up